Best healthcare and pharma stocks: how to pick them with data

The first filter is the pipeline: the portfolio of drugs the company has in development and what phase they're in. A drug goes through Phase I (safety in a few volunteers), Phase II (efficacy in hundreds of patients) and Phase III (efficacy and safety in thousands, the decisive and very expensive step) before applying for approval from the regulator (the FDA in the US, the EMA in Europe). The more advanced and broader the pipeline, the less the company depends on a single product. A good pharma company has several Phase III candidates spread across different therapeutic areas (oncology, cardiology, immunology), so that the failure of one doesn't sink the ship. Pipeline diversification is, in healthcare, what customer diversification is in other sectors.

The second filter is dependence on the patent. It's worth looking at what percentage of revenue comes from the few blockbuster drugs and when their patents expire. If 40% of billings depend on a drug whose patent expires within two years and there's nothing equivalent in the pipeline, the risk is very high. The third filter is the quality of the balance sheet and cash generation: R&D is very expensive (a new drug can cost more than a billion dollars and ten years of work), so only companies with abundant cash and little debt can sustain research without diluting their shareholders. In DeepTicker, the DeepTicker Score sums up quality and solvency in a grade from 0 to 100 compared with the sector itself, so you see at a glance whether a pharma company is Elite, Solid or Fragile versus its rivals.

Beyond the pipeline, there's a handful of metrics that separate quality healthcare companies from the rest. The gross margin and the operating margin tell you how much pricing power the business has: a pharma company with strong patents shows gross margins of 75-85%, while a drug distributor barely scrapes 3-5%. The ROIC (return on invested capital) measures whether the company genuinely turns research into sustainable profit; it's a key metric of quality analysis because a high, stable ROIC over the years is the fingerprint of a real moat, not of a lucky break. The R&D spend over sales (often 15-20% in pharma) indicates how much it reinvests in its future: too little and it'll run out of products; too much and it may be burning cash with no return.

To judge the price, the P/E alone isn't enough, because a biotech in the middle of a launch can perfectly justify a P/E of 40 and another a P/E of 12 that's a trap for having the patent about to expire. This is where discounted-cash-flow valuation comes in: instead of guessing how much the stock is "worth", DeepTicker's Reverse DCF asks the question in reverse and calculates what growth the current price is discounting. If a pharma company trades at $372 and today grows 12% a year, but the price is only justified if it grows 18% for ten years and lifts its cash margin from 20% to 32%, you decide whether you believe those two requirements knowing its pipeline. Also, the system uses the real cost of capital by industry (in healthcare and pharma it usually hovers around 7-8%, not a generic 8.5%), which changes the estimated value by between 15% and 30%.

Risk number one is the regulatory and clinical. A drug that looked promising can fail in Phase III and, in a single day, make the stock drop 30, 40 or 50%. Likewise, an FDA or EMA refusal to approve a drug, or the withdrawal of one already on the market for side effects, can be devastating. This affects above all the small biotechs, which often bet everything on a single candidate: that's why a company with no revenue and dependent on a single drug is speculation, not investment, and it's worth knowing before you go in.

The second great risk is the patent cliff already mentioned: the expiry of patents and the entry of generics. The third is the political and pricing risk: in the US, the world's largest pharmaceutical market, drug prices are a recurring subject of political debate, and any law that forces them down hits the margins of the whole sector at once. To this is added the risk of litigation (lawsuits over side effects can cost billions) and, in biotech, the risk of dilution: companies that burn cash issue new shares constantly to fund themselves, reducing the percentage of each existing shareholder. DeepTicker is honest about these cases: for a biotech with no revenue, the classic Reverse DCF doesn't apply, so the system warns you and tells you what to look at instead (pipeline, cash on hand, burn rate) rather than handing you a misleading number.

Reviewing hundreds of pharma and healthcare companies by hand is unfeasible. This is where a good screener (stock filter) changes the rules of the game. DeepTicker's stock screener lets you sift through thousands of companies with more than 140 filters and apply ready-made strategy presets, like the Graham style (classic value) or Greenblatt's Magic Formula (quality + price). For the healthcare sector you can combine criteria like a gross margin above 60%, ROIC above 15%, net debt to EBITDA below 2x and sustained revenue growth, to keep only the companies that genuinely combine quality and financial strength.

Once the list is filtered, the work isn't over: you have to open the page for each company to understand the business behind the numbers. On the stock pages you'll see at a glance the DeepTicker Score for quality, the Reverse DCF valuation verdict (Bargain, Reasonable, Demanding, Expensive or Priced-in bubble) and the figures explained one by one, no black boxes. That's DeepTicker's philosophy: widely recognized fundamental-analysis methods, made simple so anyone can invest with judgment, and designed so that the more you use it, the more you learn about finance almost without realizing it.

Finding a quality pharma company (good pipeline, high margins, patent moat, high ROIC) is only half the job. The other half is not overpaying for it. An excellent company bought at an absurd price can be a terrible investment for years, because the price already discounts all the future good news. That's why it's worth mentally separating two distinct questions: is the company good? (quality) and is it cheap or expensive today? (price). DeepTicker separates them with two tools: the DeepTicker Score answers the first (quality and competitive-advantage analysis, moat and ROIC) and the Reverse DCF answers the second (discounted-cash-flow valuation).

There's still a third question that adds perspective: is there a franchise and is the price sustainable? Value analysis calculates the EPV (the value of current earnings assuming no growth at all) and compares it with what it would cost to replicate the company from scratch; if the first is larger, there's a real franchise. And it applies a simple mathematical rule: if the growth the price is discounting persistently exceeds the cost of capital (G ≥ R), the price isn't rational, it's "a priced-in miracle". For a mature pharma company with solid patents, this test helps tell the one that's expensive but defensible apart from the one trading in pure euphoria. By combining quality, price and franchise you get a complete picture, not a hunch.